More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease control for patients  78% of patients achieved intestinal healing at both the tissue and visual level (histo-endoscopic mucosal improvement) STOCKHOLM, Feb. 21, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis (UC). These data are among the 30 company-sponsored abstracts being presented at the European Crohn's and Colitis Organisation (ECCO) 2026 conference.

Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in shares of Johnson and Johnson (NYSE: JNJ) by 11.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 73,407 shares of the company's stock after buying an additional 7,522 shares during

ANTIPODES PARTNERS Ltd boosted its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 2.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 155,963 shares of the company's stock after buying an additional 3,931 shares during the period. ANTIPODES PARTNERS Ltd's

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

American Express (AXP), Deere (DE) and Johnson and Johnson (JNJ) have removed diversity language from their board selection frameworks following engagement from t

Johnson and Johnson (NYSE: JNJ - Get Free Report) EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares in the company, valued

Fiera Capital Corp lessened its stake in shares of Johnson and Johnson (NYSE: JNJ) by 4.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,645,416 shares of the company's stock after selling 113,251 shares during the period. Johnson and

Johnson and Johnson (NYSE: JNJ - Get Free Report) EVP Timothy Schmid sold 22,623 shares of the firm's stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the sale, the executive vice president owned 26,769

Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™; results surpass current standards of care RARITAN, N.J., Feb. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma (HNSCC) that is recurrent or metastatic, PD-L1-positive, and human papillomavirus (HPV)-unrelated.